Diabetes-Associated Myelopoiesis Drives Stem Cell Mobilopathy Through an OSM-p66Shc Signaling Pathway.
Adult
Aged
Animals
Bone Marrow Transplantation
Chemokine CXCL12
/ genetics
Diabetes Mellitus
/ metabolism
Diabetes Mellitus, Experimental
/ metabolism
Female
Granulocyte Colony-Stimulating Factor
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cells
/ metabolism
Humans
Male
Mesenchymal Stem Cells
/ metabolism
Middle Aged
Myelopoiesis
/ genetics
Oncostatin M
/ genetics
Signal Transduction
Src Homology 2 Domain-Containing, Transforming Protein 1
/ genetics
Stem Cells
Journal
Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
24
01
2019
accepted:
15
03
2019
pubmed:
3
4
2019
medline:
24
12
2019
entrez:
3
4
2019
Statut:
ppublish
Résumé
Diabetes impairs the mobilization of hematopoietic stem/progenitor cells (HSPCs) from the bone marrow (BM), which can worsen the outcomes of HSPC transplantation and of diabetic complications. In this study, we examined the oncostatin M (OSM)-p66Shc pathway as a mechanistic link between HSPC mobilopathy and excessive myelopoiesis. We found that streptozotocin-induced diabetes in mice skewed hematopoiesis toward the myeloid lineage via hematopoietic-intrinsic p66Shc. The overexpression of
Identifiants
pubmed: 30936144
pii: db19-0080
doi: 10.2337/db19-0080
doi:
Substances chimiques
Chemokine CXCL12
0
Cxcl12 protein, mouse
0
Osm protein, mouse
0
Shc1 protein, mouse
0
Src Homology 2 Domain-Containing, Transforming Protein 1
0
Oncostatin M
106956-32-5
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1303-1314Informations de copyright
© 2019 by the American Diabetes Association.